Inclusion Criteria:

- Patient must give written (personally signed and dated) informed consent before
completing any study-related procedure, which means any assessment or evaluation that
would not have formed part of the normal medical care of the patient

- Patient must be 18 years old or over

- Patient must have a histologically-confirmed diagnosis of locally advanced or
metastatic prostate cancer or presenting a relapse after curative treatment which is
amenable to androgen deprivation therapy

- Patient must have an estimated survival time of greater than 8 months according to
the investigator's assessment

Exclusion Criteria:

- Patient at risk of a serious complication in the case of tumour flare (vertebral
metastases threatening spinal cord compression or with significant obstructive
uropathy)

- Patient who underwent a previous surgical castration

- Prostate cancer therapy within 2 months of baseline visit

- Patient with testosterone level below 150 ng/dL at screening